EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Association of the Affordable Care Act With Receipt of Guideline‐Concordant Adjuvant Chemotherapy for Colon and Non‐Small Cell Lung Cancer

Sriya Kudaravalli iD, Nicole Ober, Zhaojun Sun, Manisha Bhattacharya, Bruce L Jacobs, Jonathan G Yabes, Lindsay M Sabik

Cancer Medicine · 2026-07 · 15 (7)

DOI: 10.1002/cam4.72093 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Cancer Medicine, online erschienen am 08.07.2026. Verfasst von Sriya Kudaravalli und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Colonic Neoplasms, Patient Protection and Affordable Care Act. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AHRQ HHS, Agency for Healthcare Research and Quality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Access to high‐quality care, defined as receipt of guideline‐concordant treatment, is crucial for cancer outcomes, and insurance coverage is an important determinant of such care. This study investigated the association between the Affordable Care Act (ACA), which expanded insurance coverage, and receipt of guideline‐concordant adjuvant chemotherapy for non‐small cell lung cancer (NSCLC) and colon cancer.

Methods

Our retrospective study includes data from Pennsylvania Cancer Registry for patients aged 26–64 with Stage 3 colon cancer or Stage IIB/Stage IIIA/Stage IIIB NSCLC between 2010–2019. Based on review of literature and National Comprehensive Cancer Network guidelines, we focused on receipt of adjuvant chemotherapy as our measure of guideline‐concordant care. We employed interrupted time series analysis to assess changes in level and annual trend of receipt of adjuvant chemotherapy following ACA implementation. Analyses were performed overall and by subgroups defined by race/ethnicity, rurality, and ADI quartile.

Results

Across the study period, 83.9% of colon cancer and 61.7% of NSCLC patients received chemotherapy after surgery. Post‐ACA, we observed a non‐significant increase in annual rate (slope change) of post‐operative colon cancer patients receiving guideline‐concordant chemotherapy (+0.74 percentage points per year (pppy), p = 0.68), with larger, non‐significant increases among non‐White patients (+7.73 pppy, p = 0.16), rural residents (+9.74 pppy, p = 0.05), and those from ADI Q4 (high deprivation) neighborhoods (+3.92 pppy, p = 0.24). For NSCLC, there was a non‐significant decrease in annual rate of receipt of guideline‐concordant chemotherapy (−1.34 pppy, p = 0.30).

Conclusions

There were no statistically significant trends in our primary models. Estimates suggest potential increases in receipt of guideline‐concordant chemotherapy for post‐operative colon cancer patients post‐ACA, overall and among underserved groups, and potential decreases in receipt of guideline‐concordant chemotherapy for NSCLC patients post‐ACA, overall and among underserved groups. These findings warrant further study of linkages between comprehensive insurance coverage and disparities in colon cancer and NSCLC care and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsColonic NeoplasmsPatient Protection and Affordable Care ActGuideline AdherenceHumansChemotherapy, AdjuvantMiddle AgedFemaleRetrospective StudiesMaleAdultInsurance CoverageUnited StatesPennsylvaniaPractice Guidelines as TopicRegistries

Stichwörter der Autor:innen

adjuvant chemotherapyaffordable care actcancer disparitiesguideline‐concordant careinsurance coverage

Autor:innen und Institutionen

  • University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
  • Department of Urology, Division of Health Services Research, Pittsburgh, Pennsylvania, USA.
  • Center for Biostatistics and Qualitative Methodology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Sriya Kudaravalli

Förderung

  • AHRQ HHS
  • Agency for Healthcare Research and Quality

Zitieren

APA

Kudaravalli, S., Ober, N., Sun, Z., Bhattacharya, M., Jacobs, B. L., Yabes, J. G., & Sabik, L. M. (2026). Association of the Affordable Care Act With Receipt of Guideline‐Concordant Adjuvant Chemotherapy for Colon and Non‐Small Cell Lung Cancer. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72093

Vancouver

Kudaravalli S, Ober N, Sun Z, Bhattacharya M, Jacobs BL, Yabes JG, et al. Association of the Affordable Care Act With Receipt of Guideline‐Concordant Adjuvant Chemotherapy for Colon and Non‐Small Cell Lung Cancer. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72093

BibTeX
@article{Kudaravalli2026,
  author = {Kudaravalli, Sriya and Ober, Nicole and Sun, Zhaojun and Bhattacharya, Manisha and Jacobs, Bruce L and Yabes, Jonathan G and Sabik, Lindsay M},
  title = {Association of the Affordable Care Act With Receipt of Guideline‐Concordant Adjuvant Chemotherapy for Colon and Non‐Small Cell Lung Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cam4.72093}
}
Kostenlos starten →